NVNO
enVVeno Medical Corp
Next earnings Jul 29, 2026 (after close) · consensus $-0.27 EPS, $1.02M rev
Last earnings -10.8% on 2026-04-29
$10.84
▼ -1.90%$10.84▼ -92.41%
over 1Y
L $8.67EODHDH $183.75
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.9%
1W+3.2%
1M-2.6%
3M+2.4%
YTD-11.5%
1Y-92.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Conservative balance sheet (liabilities/equity 0.09x); but revenue fell -83.3% YoY.
Revenue (FY2019) $31.2K · FY2019
enVVeno Medical Corp shows $31.2K in FY2019 revenue (-83.3% YoY), a -62324.4% net margin, and -71.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$16.9M | -$24.9M | -$25.2M | -$23.8M | -$20.9M |
| Net income | -$16.5M | -$24.7M | -$23.5M | -$21.8M | -$19.5M |
| Diluted EPS | — | -$2.20 | -$1.91 | -$44.53 | -$33.06 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.04M
EV / EBITDA—
EV / Sales129.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-274.0%
FCF yield-219.2%
Quality & risk
ROIC (est.)-60.9%
Free cash flow-$15.6M
Total debt—
Net cash$3.06M
Altman Z-Score-7.61 distress
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-96.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-12open ↗144Filing2026-06-11open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-06open ↗8-KPeriod ending 2026-04-292026-04-29open ↗S-8Filing2026-03-26open ↗10-KPeriod ending 2025-12-312026-03-26open ↗4Period ending 2026-03-122026-03-13open ↗144Filing2026-03-12open ↗SCHEDULE 13DFiling2026-02-20open ↗SCHEDULE 13DFiling2026-02-20open ↗
Frequently asked
- Is enVVeno Medical Corp (NVNO) a buy?
- NVNO currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.09x); but revenue fell -83.3% YoY.
- What is enVVeno Medical Corp's quality score?
- NVNO scores 37.11764705882352/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001661053, latest 10-Q filed 2026-05-06) · EODHD · as of 6/23/2026, 12:09:25 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.